Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Laryngeal Muscles | 6 | 2015 | 16 | 2.640 |
Why?
|
Muscular Atrophy | 6 | 2015 | 70 | 1.530 |
Why?
|
Aging | 7 | 2017 | 941 | 1.310 |
Why?
|
Deglutition | 4 | 2017 | 29 | 1.180 |
Why?
|
Muscle, Skeletal | 8 | 2016 | 513 | 1.130 |
Why?
|
Ubiquitin-Protein Ligases | 3 | 2015 | 35 | 1.010 |
Why?
|
Muscle Proteins | 3 | 2015 | 59 | 1.010 |
Why?
|
Hyoid Bone | 2 | 2015 | 5 | 0.970 |
Why?
|
Carcinoma, Adenoid Cystic | 2 | 2017 | 7 | 0.730 |
Why?
|
Salivary Gland Neoplasms | 2 | 2017 | 13 | 0.720 |
Why?
|
Deglutition Disorders | 3 | 2017 | 50 | 0.690 |
Why?
|
MicroRNAs | 2 | 2017 | 180 | 0.620 |
Why?
|
Respiratory Aspiration | 2 | 2017 | 21 | 0.610 |
Why?
|
Acute Lung Injury | 2 | 2015 | 33 | 0.580 |
Why?
|
Cesium Radioisotopes | 1 | 2015 | 5 | 0.530 |
Why?
|
Gamma Rays | 1 | 2015 | 25 | 0.520 |
Why?
|
Muscle Contraction | 2 | 2017 | 113 | 0.510 |
Why?
|
Animals | 17 | 2017 | 7450 | 0.470 |
Why?
|
Rats | 9 | 2014 | 1586 | 0.440 |
Why?
|
Imaging, Three-Dimensional | 1 | 2013 | 132 | 0.430 |
Why?
|
Pharyngeal Muscles | 1 | 2012 | 5 | 0.430 |
Why?
|
Neuromuscular Junction | 2 | 2017 | 71 | 0.430 |
Why?
|
Myosin Heavy Chains | 2 | 2012 | 89 | 0.420 |
Why?
|
Levodopa | 1 | 2012 | 14 | 0.420 |
Why?
|
Reflex | 1 | 2012 | 15 | 0.420 |
Why?
|
Dopamine Agents | 1 | 2012 | 19 | 0.420 |
Why?
|
Quadriceps Muscle | 1 | 2012 | 34 | 0.410 |
Why?
|
Extremities | 1 | 2012 | 51 | 0.400 |
Why?
|
Sprains and Strains | 3 | 2005 | 11 | 0.370 |
Why?
|
Male | 18 | 2017 | 19091 | 0.340 |
Why?
|
Laryngeal Diseases | 1 | 2009 | 10 | 0.340 |
Why?
|
Receptors, Dopamine D1 | 1 | 2009 | 19 | 0.340 |
Why?
|
Rats, Sprague-Dawley | 6 | 2014 | 738 | 0.300 |
Why?
|
Motilin | 1 | 2007 | 1 | 0.290 |
Why?
|
Gastrointestinal Motility | 1 | 2007 | 2 | 0.290 |
Why?
|
Female | 14 | 2017 | 19859 | 0.290 |
Why?
|
Muscle Fibers, Fast-Twitch | 3 | 2017 | 29 | 0.280 |
Why?
|
Amygdala | 1 | 2007 | 60 | 0.270 |
Why?
|
Troponin T | 2 | 2017 | 80 | 0.260 |
Why?
|
Wasting Syndrome | 2 | 2015 | 13 | 0.240 |
Why?
|
Cumulative Trauma Disorders | 1 | 2004 | 13 | 0.240 |
Why?
|
Lipid Peroxidation | 1 | 2004 | 32 | 0.240 |
Why?
|
Ascorbic Acid | 1 | 2004 | 23 | 0.240 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2004 | 17 | 0.240 |
Why?
|
Estrogens | 1 | 2004 | 167 | 0.220 |
Why?
|
Exercise Therapy | 2 | 2017 | 268 | 0.220 |
Why?
|
Regeneration | 1 | 2004 | 170 | 0.220 |
Why?
|
Lung Neoplasms | 2 | 2016 | 409 | 0.210 |
Why?
|
Disease Models, Animal | 4 | 2013 | 1012 | 0.210 |
Why?
|
Muscle Fibers, Skeletal | 2 | 2012 | 109 | 0.200 |
Why?
|
Laryngeal Nerves | 2 | 2012 | 4 | 0.190 |
Why?
|
Receptors, Dopamine D2 | 2 | 2014 | 79 | 0.190 |
Why?
|
Mice | 3 | 2017 | 2476 | 0.180 |
Why?
|
Cell Line, Tumor | 3 | 2017 | 725 | 0.180 |
Why?
|
Humans | 12 | 2017 | 31836 | 0.180 |
Why?
|
Chemokines | 2 | 2016 | 36 | 0.170 |
Why?
|
Young Adult | 3 | 2017 | 2603 | 0.170 |
Why?
|
Mice, Inbred C57BL | 3 | 2016 | 766 | 0.160 |
Why?
|
Aged, 80 and over | 4 | 2017 | 3988 | 0.160 |
Why?
|
Adult | 4 | 2017 | 9327 | 0.150 |
Why?
|
Physical Conditioning, Animal | 2 | 2015 | 32 | 0.150 |
Why?
|
Receptors, Retinoic Acid | 1 | 2017 | 9 | 0.150 |
Why?
|
Oxidoreductases Acting on CH-CH Group Donors | 1 | 2017 | 9 | 0.150 |
Why?
|
Salivary Glands | 1 | 2017 | 14 | 0.150 |
Why?
|
Age Factors | 3 | 2017 | 1187 | 0.150 |
Why?
|
Muscle Denervation | 1 | 2017 | 28 | 0.150 |
Why?
|
Lipopolysaccharides | 2 | 2015 | 109 | 0.140 |
Why?
|
Fetal Proteins | 1 | 2016 | 7 | 0.140 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2016 | 10 | 0.140 |
Why?
|
T-Box Domain Proteins | 1 | 2016 | 14 | 0.140 |
Why?
|
Receptors, Chemokine | 1 | 2016 | 9 | 0.140 |
Why?
|
Nerve Tissue Proteins | 1 | 2017 | 120 | 0.140 |
Why?
|
Aged | 6 | 2017 | 10288 | 0.140 |
Why?
|
Muscle Fibers, Slow-Twitch | 2 | 2016 | 20 | 0.140 |
Why?
|
Calpain | 1 | 2016 | 13 | 0.130 |
Why?
|
Gait | 1 | 2017 | 140 | 0.130 |
Why?
|
Gene Expression | 1 | 2017 | 334 | 0.130 |
Why?
|
Calcium Channels, L-Type | 1 | 2016 | 44 | 0.130 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 52 | 0.130 |
Why?
|
Sex Factors | 2 | 2017 | 662 | 0.130 |
Why?
|
Linear Models | 2 | 2013 | 449 | 0.130 |
Why?
|
Blotting, Western | 1 | 2015 | 292 | 0.120 |
Why?
|
Posture | 1 | 2015 | 54 | 0.120 |
Why?
|
Retrospective Studies | 2 | 2013 | 3488 | 0.120 |
Why?
|
Neutrophils | 1 | 2015 | 112 | 0.120 |
Why?
|
Vocal Cords | 1 | 2014 | 9 | 0.120 |
Why?
|
Autoreceptors | 1 | 2014 | 9 | 0.120 |
Why?
|
Tracheal Stenosis | 1 | 2013 | 5 | 0.120 |
Why?
|
Amphetamine | 1 | 2014 | 37 | 0.110 |
Why?
|
Observer Variation | 1 | 2013 | 105 | 0.110 |
Why?
|
Mandible | 1 | 2013 | 39 | 0.110 |
Why?
|
Trachea | 1 | 2013 | 54 | 0.110 |
Why?
|
Reference Values | 1 | 2013 | 247 | 0.110 |
Why?
|
Velopharyngeal Sphincter | 1 | 2012 | 4 | 0.110 |
Why?
|
Oxidative Stress | 2 | 2005 | 229 | 0.110 |
Why?
|
Dopamine Uptake Inhibitors | 1 | 2014 | 117 | 0.110 |
Why?
|
Mice, Knockout | 1 | 2014 | 444 | 0.110 |
Why?
|
Databases, Protein | 1 | 2012 | 13 | 0.100 |
Why?
|
Ultrasonography | 1 | 2015 | 378 | 0.100 |
Why?
|
Tongue | 1 | 2012 | 13 | 0.100 |
Why?
|
Head | 1 | 2012 | 51 | 0.100 |
Why?
|
Species Specificity | 1 | 2012 | 87 | 0.100 |
Why?
|
Protein Isoforms | 1 | 2012 | 57 | 0.100 |
Why?
|
Rats, Inbred F344 | 1 | 2012 | 133 | 0.100 |
Why?
|
Mass Spectrometry | 1 | 2012 | 103 | 0.100 |
Why?
|
Stem Cell Transplantation | 1 | 2013 | 209 | 0.100 |
Why?
|
Reaction Time | 1 | 2012 | 117 | 0.100 |
Why?
|
Multivariate Analysis | 1 | 2013 | 686 | 0.100 |
Why?
|
Reconstructive Surgical Procedures | 1 | 2013 | 199 | 0.100 |
Why?
|
Radiography | 1 | 2012 | 376 | 0.100 |
Why?
|
Proteomics | 1 | 2012 | 94 | 0.100 |
Why?
|
Reproducibility of Results | 1 | 2013 | 764 | 0.100 |
Why?
|
Dopamine | 1 | 2014 | 232 | 0.100 |
Why?
|
Muscle Strength | 1 | 2012 | 159 | 0.100 |
Why?
|
Adiposity | 1 | 2012 | 198 | 0.090 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 1527 | 0.090 |
Why?
|
Salicylamides | 1 | 2009 | 4 | 0.090 |
Why?
|
Dopamine Antagonists | 1 | 2009 | 22 | 0.080 |
Why?
|
Benzazepines | 1 | 2009 | 21 | 0.080 |
Why?
|
Obesity | 1 | 2017 | 1158 | 0.080 |
Why?
|
Electromyography | 1 | 2009 | 59 | 0.080 |
Why?
|
Cohort Studies | 1 | 2013 | 1824 | 0.080 |
Why?
|
Electric Stimulation | 1 | 2009 | 104 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 1 | 2013 | 912 | 0.080 |
Why?
|
Time Factors | 2 | 2015 | 2146 | 0.080 |
Why?
|
Risk Assessment | 1 | 2013 | 1431 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2009 | 629 | 0.070 |
Why?
|
Receptors, Gastrointestinal Hormone | 1 | 2007 | 1 | 0.070 |
Why?
|
Receptors, Neuropeptide | 1 | 2007 | 3 | 0.070 |
Why?
|
Peptides, Cyclic | 1 | 2007 | 4 | 0.070 |
Why?
|
Injections, Intraventricular | 1 | 2007 | 13 | 0.070 |
Why?
|
Microinjections | 1 | 2007 | 35 | 0.070 |
Why?
|
Electrophysiology | 1 | 2007 | 70 | 0.070 |
Why?
|
Neoplasm Invasiveness | 2 | 2016 | 194 | 0.070 |
Why?
|
Creatine Kinase | 1 | 2004 | 11 | 0.060 |
Why?
|
Desmin | 1 | 2004 | 12 | 0.060 |
Why?
|
Superoxide Dismutase | 1 | 2005 | 44 | 0.060 |
Why?
|
Vitamin E | 1 | 2004 | 23 | 0.060 |
Why?
|
Glutathione | 1 | 2004 | 44 | 0.060 |
Why?
|
Vimentin | 1 | 2004 | 10 | 0.060 |
Why?
|
Ovariectomy | 1 | 2004 | 149 | 0.060 |
Why?
|
Antioxidants | 1 | 2004 | 114 | 0.060 |
Why?
|
Random Allocation | 1 | 2004 | 218 | 0.060 |
Why?
|
Oxidation-Reduction | 1 | 2004 | 268 | 0.060 |
Why?
|
Neurons | 1 | 2007 | 409 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2004 | 531 | 0.050 |
Why?
|
Signal Transduction | 2 | 2016 | 687 | 0.050 |
Why?
|
Laryngoscopy | 1 | 2017 | 40 | 0.040 |
Why?
|
Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2017 | 8 | 0.040 |
Why?
|
Prospective Studies | 2 | 2013 | 2277 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 1 | 2017 | 90 | 0.040 |
Why?
|
MAP Kinase Signaling System | 1 | 2016 | 61 | 0.040 |
Why?
|
Action Potentials | 1 | 2017 | 177 | 0.030 |
Why?
|
Muscle Fatigue | 1 | 2016 | 12 | 0.030 |
Why?
|
Isometric Contraction | 1 | 2016 | 23 | 0.030 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2016 | 18 | 0.030 |
Why?
|
Protein Stability | 1 | 2016 | 25 | 0.030 |
Why?
|
Synaptic Transmission | 1 | 2017 | 116 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2016 | 77 | 0.030 |
Why?
|
Sulfonamides | 1 | 2016 | 67 | 0.030 |
Why?
|
Protein Binding | 1 | 2016 | 201 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2016 | 221 | 0.030 |
Why?
|
Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2015 | 9 | 0.030 |
Why?
|
Transcription, Genetic | 1 | 2016 | 137 | 0.030 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2015 | 24 | 0.030 |
Why?
|
Pulmonary Alveoli | 1 | 2015 | 20 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 208 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2016 | 108 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2016 | 261 | 0.030 |
Why?
|
Cell Line | 1 | 2016 | 434 | 0.030 |
Why?
|
Respiratory Distress Syndrome, Adult | 1 | 2015 | 52 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2017 | 493 | 0.030 |
Why?
|
Incidence | 1 | 2017 | 1192 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2016 | 598 | 0.030 |
Why?
|
Dogs | 1 | 2013 | 116 | 0.030 |
Why?
|
Receptors, Dopamine D3 | 1 | 2014 | 33 | 0.030 |
Why?
|
Corpus Striatum | 1 | 2014 | 60 | 0.030 |
Why?
|
Nucleus Accumbens | 1 | 2014 | 94 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2013 | 291 | 0.030 |
Why?
|
Isotonic Contraction | 1 | 2012 | 8 | 0.030 |
Why?
|
Myofibrils | 1 | 2012 | 9 | 0.030 |
Why?
|
Self Administration | 1 | 2014 | 297 | 0.030 |
Why?
|
Motor Activity | 1 | 2015 | 325 | 0.030 |
Why?
|
Exercise | 1 | 2017 | 663 | 0.020 |
Why?
|
Inflammation | 1 | 2015 | 540 | 0.020 |
Why?
|
Middle Aged | 2 | 2017 | 11824 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2013 | 345 | 0.020 |
Why?
|
Risk Factors | 1 | 2017 | 3851 | 0.020 |
Why?
|
United States | 1 | 2017 | 3925 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2013 | 2271 | 0.020 |
Why?
|
Tissue Engineering | 1 | 2013 | 655 | 0.020 |
Why?
|